Cargando…

SLE - Rituximab in lupus

B cells are essential to the development of systemic lupus erythematosus (SLE). The chimeric monoclonal antibody rituximab depletes B cells by targeting the pan-B-cell surface marker CD20. Preliminary experience with this agent in SLE and other autoimmune diseases has been encouraging. Controlled tr...

Descripción completa

Detalles Bibliográficos
Autor principal:	Eisenberg, Robert
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2003
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165056/ https://www.ncbi.nlm.nih.gov/pubmed/12823844 http://dx.doi.org/10.1186/ar759

Ejemplares similares

SLE – Hematopoietic stem cell transplantation for systemic lupus erythematosus
por: Burt, Richard K, et al.
Publicado: (2003)

SLE - Systemic lupus erythematosus: a BLySful, yet BAFFling, disorder
por: Stohl, William
Publicado: (2003)

SLE - Practical and theoretical barriers to the prevention of accelerated atherosclerosis in systemic lupus erythematosus
por: Costenbader, Karen H, et al.
Publicado: (2003)

SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus
por: Aringer, Martin, et al.
Publicado: (2003)

Use of Rituximab in child with SLE and myocardial involvement
por: Balan, S, et al.
Publicado: (2008)

SLE‐associated myelitis successfully treated by rituximab
por: Khabbazi, Alireza, et al.
Publicado: (2022)

Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again
por: Eisenberg, Robert
Publicado: (2006)

Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review()
por: Pirone, Carmelo, et al.
Publicado: (2017)

Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus?
por: Lekpa, Fernando Kemta, et al.
Publicado: (2021)

SLE and purine metabolizing ecto-enzymes
por: Cronstein, Bruce N.
Publicado: (2021)

Efficacy and Safety of Rituximab Therapy for Lupus Nephritis Among SLE Female Patients; a Retrospective Hospital-Based Study
por: Abdelkarim Aloub, Khansa Osama, et al.
Publicado: (2022)

How to predict the prognosis in juvenile-onset SLE?
por: Yamamoto, Hiroyasu
Publicado: (2021)

COVID-19 after rituximab therapy in cSLE patients
por: Nelson, Meghan Corrigan, et al.
Publicado: (2023)

Vasculitis and Systemic Lupus Erythematous (SLE)
por: Cortis, Elisabetta, et al.
Publicado: (2015)

Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE
por: Gilbert, Mileka, et al.
Publicado: (2021)

Effective use of rituximab in combination with low dose cyclophosphamide in childhood onset systemic lupus erythematosus (SLE) with relapsing class IV nephritis
por: Miettunen, PM, et al.
Publicado: (2008)

Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE) †
por: Ponticelli, Claudio, et al.
Publicado: (2010)

Malignancy in Systemic Lupus Erythematosus (SLE) Patients
por: Cader, Rizna Abdul, et al.
Publicado: (2018)

Dissociation in SLE: A part of lupus fog?
por: Monahan, Rory C, et al.
Publicado: (2021)

Involvement of Gut Microbiota in SLE and Lupus Nephritis
por: Mohd, Rozita, et al.
Publicado: (2023)

Commentary: Rituximab in scleritis
por: Dutta Majumder, Parthopratim
Publicado: (2020)

A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE
por: van Dam, Laura S, et al.
Publicado: (2020)

Liver involvement in juvenile systemic lupus erythematosus (SLE)
por: Mariniello, Generosa, et al.
Publicado: (2011)

Pauci-immune Glomerulonephritis in Systemic Lupus Erythematosus (SLE)
por: Liebowitz, Jason, et al.
Publicado: (2018)

Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New
por: Basta, Fabio, et al.
Publicado: (2020)

Canadian workplace experiences of systemic lupus erythematosus (SLE)
por: Cardwell, Francesca S, et al.
Publicado: (2021)

SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus
por: Smith, Michael A., et al.
Publicado: (2019)

What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population‐Based Study of Maternal and Fetal Outcomes in SLE and Pre‐SLE
por: Arkema, Elizabeth V., et al.
Publicado: (2016)

Can we predict if patients with SLE will require more than one cycle of rituximab?
por: Fernández González, Raquel, et al.
Publicado: (2021)

Rituximab use in late antibody-mediated rejection
por: Bansal, S. B.
Publicado: (2016)

Sex Differences in Monocyte Activation in Systemic Lupus Erythematosus (SLE)
por: Jiang, Wei, et al.
Publicado: (2014)

Advances in Systemic Lupus Erythematosus (SLE): A case for optimism
por: Fanouriakis, Antonis, et al.
Publicado: (2017)

44 Pediatric onset systemic lupus erythematosus (p-SLE)
por: Maher, Sheren
Publicado: (2022)

Colonic basidiobolomycosis in a patient with systemic lupus erythematosus (SLE)
por: Barahimi, Elham, et al.
Publicado: (2022)

An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management
por: Ameer, Muhammad Atif, et al.
Publicado: (2022)

Diet and Systemic Lupus Erythematosus (SLE): From Supplementation to Intervention
por: Jiao, Hanxiao, et al.
Publicado: (2022)

Urinary Aspergillosis in a Patient with Systemic Lupus Erythematosus (SLE)
por: Toledo, Mayara Gabriele, et al.
Publicado: (2023)

Rituximab for treatment of severe lupus nephritis
por: Baskin, E, et al.
Publicado: (2008)

Standardised incidence ratios (SIRs) for cancer after renal transplant in systemic lupus erythematosus (SLE) and non-SLE recipients
por: Ramsey-Goldman, Rosalind, et al.
Publicado: (2016)

B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design
por: Reddy, Venkat, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8uv3uhiurr24rkunu9h5e9qkrj